ABSTRACT
INTRODUCTION
Highly active antiretroviral therapy (HAART) is successful in increasing the lifespan of human immunodeficiency virus (HIV) infected individuals but toxic side effects and the development of resistant viral strains could eventually render these drugs ineffective.
When drug failure and or cross resistance to the same class of compounds occurs, treatment options become limited [1] . Identifying novel compounds which can be used in combination with HAART while maintaining a better resistance profile is therefore very important.
Gold-based drugs, very well known for rheumatoid arthritis (RA) treatment [2, 3] , also demonstrate anti-HIV activity, reviewed by Fonteh et al., 2010 [4] . Ligands play a crucial role in the synthesis of gold-based compounds in that their complexation to metals not only gives rise to stable compounds, but in some cases leads to better activities and/or didanosine boosts immune parameters including increases in CD4+ cell count [20] . The HU-didanosine combination decreases deoxyribonucleotides (dNTPs) resulting in an increase in the dNTP analogue (didanosine) which is a nucleotide reverse transcriptase inhibitor resulting in an increase in anti-HIV activity [21, 22] . The combination of cytostatic drugs with anti-viral agents, results in an overall significantly beneficial anti-HIV effect [13, 19, 20, 23, 24] . Lori and colleagues [13, 19] named this combination virostatics and defined it as a class of emerging anti-HIV agents which are characterised by the combination of a drug directly inhibiting virus production (viro) e.g. didanosine and one indirectly inhibiting virus replication by reducing cellular proliferation (static) e.g.
HU.
The current approach of HIV medicine (HAART) is aimed at the reduction in viral load and prevention of further loss of CD4+ cells [19] . However, viral resistance (also observed for the recently approved integrase inhibitors [25] ) is still a major concern when using combinations that directly target the virus. The advantage incurred from having a drug that results in an overall better resistance profile like HU in the HUdidanosine combination is arguably a better option than combinations for which resistance could easily become a problem rendering them obsolete. This is because HU's antiviral activity is linked to the inhibition of a cellular enzyme (ribonucleotide reductase or RNR) which is not prone to the same resistance concerns as viral enzymes [26] . This paper is a documentation of the synthesis and characterisation of complexes 1-4 and investigation of their possible anti-HIV mechanism of action. Findings presented suggest a cytostatic mechanism of inhibition of viral infectivity by two of the tested complexes (3 and 4). The cytostatic nature of the gold Tscs compounds 3 and 4 reported here, and their observed anti-viral activity supports their potential for incorporation in virostatic cocktails.
MATERIALS AND METHODS

Reagents, Starting Materials and Instrumentation
Gold starting material, HAuCl 4 .4H 2 O, was synthesised using procedures reported by Block, 1953 [27] and bis(thiosemicarbazone) ligands (L1-L4) according to methods by West et al., 1997 [28] . All the solvents were purchased from Merck and dried using conventional methods. Ligands L1-L4 and complexes 1-4 (collectively referred to as the compounds from here onwards) were prepared under dry, deoxygenated nitrogen atmosphere using Schlenk techniques. IR spectra were recorded as KBr pellets on a Perkin-Elmer, paragon 1000 PC FTIR spectrophotometer. Ligand L1 (0.12 g, 0.54 mmol) was added to an ethanol solution (20 mL) of HAuCl 4 .4H 2 O (0.22 g, 0.54 mmol) leading to the formation of a brown suspension. The reaction was left to stir for 1.5 h during which time the suspension turned from brown to a wine-red solution. The reaction was stopped, solvent reduced in vacuo and a brown-green precipitate isolated as the product (1). Yield = 0.17 g (62%). 
Effect of the Complexes on Viral Infectivity, Viability and Proliferation
The TZM-bl cell line is a HeLa clone that was engineered to express CD4, chemokine receptor (CCR)5 and CXC chemokine receptor (CXCR)4 and contains an integrated reporter gene for β galactosidase and luciferase under the control of an HIV-1 long terminal repeat [29] . This cell line was used for infectivity determination and the assay was performed at the laboratory of Prof. Lynn Morris at the National Institute of Communicable Diseases (NICD, South Africa) according to the protocol described by David Montefiori in 2004 [30] . Du151.2, an isolate of two phylogenetically distinct subtype C strains [31] , at a dilution that gave 50,000 + 15000 relative light units (tissue culture infectious dose -TCID) was pre-treated with complexes 1-4 for 1 h followed by the addition of 100 µL of cells (1x10 5 cells/mL) to a final volume of 250 µL. Luciferase activity was measured after 48 h using the bright glo substrate solution (Promega, Wisconsin, USA). Infectivity inhibition was determined as a percentage using the formula = 100-[(test wells-CC)/(VC-CC)] X100, where CC= cell control and VC= virus control.
Considering that infectivity data can be influenced by cell death, cell viability experiments were performed at the same concentrations of 1-4 used in the infectivity assay to ensure that any observed signals as a result of luciferase activity did not stem from the fact that cell viability had been compromised. This was done using 3- ( as the cells adhere. The more the cells attach to the electrodes, the higher the electronic impedence which is read as cell index (CI). This assay has been described for the measurement of cytotoxicity [32] [33] [34] and can be used to determine other cellular parameters such as cell proliferation, cytotoxicity start time, cell recovery and cell response patterns [34] represented by CI changes which could either be proliferating (increasing CI), cytotoxic (decreasing CI) or cytostatic (stable CI).
Effect of the Compounds on Immune Cell Proliferation and Function
To investigate whether the compounds had an effect on immune system cell function (CD4+ and CD8+ lymphocytes) which in turn could be associated with the antiviral or cytostatic activity observed, cell proliferation and the production of a key proinflammatory cytokine, tumour necrosis factor alpha (TNF-α) and an anti-inflammatory cytokine, interferon gamma (IFN-γ) were monitored using multi-parametric flow cytometry. These studies were performed on peripheral blood mononuclear cells PBMCs were isolated by density gradient centrifugation using lymphocyte separation medium (Cambrex BioScience, Maryland, USA). The carboxyflourescein succinimidyl ester (CFSE, Molecular Probes, Oregon, USA) dye was used for monitoring proliferation from a "live gate" by incorporating propidium iodide (PI) which helps to exclude background staining from dead cells. CFSE is a cell proliferation dye that binds spontaneously and irreversibly couples to cellular proteins by reaction with lysine side chains and other available amines [35] . As the cells divide, the intensity of the dye is spread between daughter cells allowing for proliferation monitoring by flow cytometry. 
Lipophilicity Determination
The shake flask method and in silico prediction using the Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) protocol in Discovery studio (DS ® ) Client 2.5.5 (Accelrys®, California, USA) were employed in determining the lipophilicity of the complexes.
A modification of the shake flask method by Yousif et al., 2009 [36] was performed.
Phosphate buffered saline (PBS, sterile filtered, pH 7.4) was used as the aqueous phase while the organic phase was 1-octanol (Sigma Aldrich, Missouri, USA). (Table   S1) and IR spectroscopic data analysis shows similarities in their structures. Complexes [37] recently reported the synthesis of complex 3 which was prepared through a different synthetic protocol than that described here.
Fig. 1
Single crystals of 4 (as a representative compound) were grown from ethanol solutions and the structure elucidated (Fig. 2) . However, the crystallographic data acquired was indicative of poor quality crystals. This is discernible from the R factor of 7.26% and the poor atomic displacement parameters (ellipsoids). Attempts made to re-grow the crystals gave the same results. Crystallographic data are therefore not discussed in full but are presented as supplementary material along with the bond lengths and angles (Table S2a and S2b). The structure (Fig. 2) is presented to show that the connectivity and coordination of the bis(thiosemicarbazones) to gold(III) is through two iminic nitrogen atoms and two sulfur atoms. The complex was isolated as a salt with a chloride as the counterion. There was a dose dependent decrease in infection from 0.2 to 25 µM (Fig. 3) . Viability was assessed (using MTT) to determine whether the inhibition observed was specific
and not due to complex-initiated cell death. MTT viability data suggests that what appeared to be inhibition was a result of cell death, except in the case of 3 where at 12.5 µM, there was a 98% inhibition of infection while the cells were 67% viable (Fig. 3) .
The IC 50 value of 3 against DU151.2's infection of the TZM-bl cell line was 6.8±0.6 µM while that of 4 was 5.3±0.4 µM. These concentrations are known to be physiologically relevant for gold compounds. Complexes 1 and 2 were less specific than 3 and 4 as the inhibitory concentrations were also very toxic (Fig. 3) . The ligands (L3 and L4) and gold starting material HAuCl 4 .4H 2 O did not show any appreciable inhibition of Du151.2's infectivity. As a positive control for infectivity inhibition, a neutralising antibody control (designated Bb-pool) was used which always presented a dose response inhibition.
To verify whether inhibition of infection by 3 and 4 was through interaction with components on the surface of the virus (since the virus was pre-treated with the compounds), time of addition studies were performed for 3 and 4. The cells were pretreated with the compounds prior to addition of virus and the rest of the assay performed as previously described (2.3). The IC 50 values obtained (6.2±0.5 and 6.0±1.3 respectively) were not significantly different from when virus was pre-treated with compounds (6.8±0.6 and 5.3±0.4). This finding suggests that inhibition of infectivity was not imposed primarily on viral surface components but could have been as a result of the compounds effect on viral targets either within the cell or on its surface thus indirectly limiting infectivity. The main variable in this time of addition studies was the exposure time.
Fig. 3
When the RT-CES device (which monitors cell response patterns in real time) was used for proliferation and viability assessment, an interesting observation was made for complex 4 indicating that the compound was cytostatic rather than cytotoxic at 5 and 10 µM (Fig. 4a ). Compared to 10 µM of auranofin which killed the TZM-bl cells after 10 to 20 h of addition (Fig. 4a ), cells treated with 4 initially underwent an uptake phase and then maintained a dose dependent cytostasis for the duration of the experiment (Fig.   4a ). The inhibition of infectivity results for complex 4 at 6.25 and 12.5 µM were 72 and 98% respectively (Fig. 3) . The MTT assay suggests toxicity at 6.25 (48.5% viability) and 12.5 µM (42.8% viability) for complex 4 ( Fig. 3) but the RT-CES data demonstrates the compound's cytostatic effect (Fig. 4a) . The viability of cells exposed to 10 µM of auranofin (control for cell death) was 20% (CC 50 =5±0.8 µM) also confirming the RT-CES findings for this compound. Data collected with the RT-CES assay is more reliable because it is not prone to the shortcomings of the MTT assay such as sensitivity to environmental conditions and dependence on the cells' metabolism of formazan, [38, 39] . Complex 4 may therefore have viral inhibitory activity through a cytostatic mechanism, a finding which has been reported for other anti-HIV agents such as HU [13, 19, 20, 23] . Lori et al., in 2005 [13] showed that a cytostatic 10 µM concentration of HU inhibited cell proliferation and suppressed HIV-1 replication in vitro. In a virostatic combination with didanosine, the indirect antiviral effect of HU and the direct antiviral effect of didanosine resulted in an overall beneficial effect [13, 19, 20, 23, 24] . On its own, compound 4 exhibited antiviral activity (lowering infectivity of TZM-bl cells by Du
151.2). Considering that cytostatic anti-viral activity is not ideal in the treatment of HIV
(because it lowers CD4 counts), 4 would have to be combined with an anti-viral agent like didanosine in a virostatics cocktail just as in the HU-didanosine combination. In addition, because the anti-viral activity of other Tscs have been postulated [8] and
shown [40] to be through the lowering of dNTP pools by inhibition of RNR we postulate that the antiviral activity of 4 (a gold(III) Tscs compound) is probably as a result of its inhibition of this enzyme as well.
Supporting data on this cytostatic tendency of 4 is provided in Fig. S1 (experimental repeats using RT-CES). In all cases the ligand, L4 did not show any significant cytostatic activity (Fig 4b, Fig. S1 ) compared to its complementary complex, 4, suggesting that the activity observed for 4 was as a result of complexation of L4 with gold. 
Effect of the compounds on immune cell proliferation and function
The cytostatic nature of 4 as well as 3 at 5 µM was also observed in PHA-P stimulated PBMCs using the CFSE dye (Fig. 5) . The intensity of the CFSE dye divided between did not affect cell proliferation further confirming findings from RT-CES analysis for L4.
The CFSE data for 3 and 4 as well as the RT-CES analysis of 4 attest to the fact that these compounds have cytostatic tendencies. This further supports the absence of a direct anti-viral effect as seen from the time of addition studies suggesting that a cellular and not a viral target was involved. The CFSE data supports RT-CES (cytostasis) rather than MTT (cytotoxicity) data.
Fig. 5
To investigate whether the compounds have an effect on immune system cell activity which may further support their ability to suppress HIV replication, PBMCs from 12 treatment-naïve, HIV infected individuals were treated with L2, L4, 2 and 4 and their effects monitored using multi-parametric flow cytometry. Compound 4 caused a significant (p=0.0049) decrease in the CD4+ cell expression (Fig. 6) . The same compound did not have a significant effect on CD4+ cells production of TNF-α and IFN-γ ( Fig. S2b and c ) but its ligand (L4) increased TNF-α production with a significant p value of 0.04 (Fig. S2c) . TNF-α is a pro-inflammatory cytokine and by enhancing its secretion, L4 could help in driving pathogenesis. This is because TNF-α increase has been associated with HIV disease progression in vivo [41] . This effect appears to be diminished in 4 as a result of complexation with gold making 4 a better drug candidate.
CD8+ cell expression was not altered for either L2, L4, 2 or 4 treated cells (Fig. S2d) and no significant effect on TNF-α and IFN-γ production was seen for any of these treatments ( Fig. S2e and f) . HU has been reported to exert a cytostatic but not an immunosuppressive effect on T lymphocytes by not decreasing the production of T helper (h)1 or Th2 cytokines [42] . In our experience 4 did not affect TNF-α and IFN-γ (both Th1 cytokines) production. Compound 4 like HU affects the immune system with respect to its cytostatic effect on CD4+ T lymphocytes but when measuring intracellular cytokine levels 4 had no effect on cytokine production by CD4+ and CD8+ cells.
Concerns regarding compounds like HU which suppress CD4+ cell expression and limit HIV infectivity through a cytostatic mechanism have been raised since these cells are needed by immunocompromised individuals. Several clinical trials e.g. the Research
Institute for Genetic and Human Therapy (RIGHT) 411 trial [14] , the AIDS Clinical Trials
Group (ACTG) 307 study [15] , the Swiss HIV Study cohort [16] and the Bristol-Myers Squibb (BMS) 055 study (Federici et al., hydroxyurea in combination regimens for the treatment of antiretroviral naïve, HIV-infected adults. XII International Conference on AIDS. Geneva, June 1998, abstract 287/12235) that used an optimal cytostatic dose of HU in combination with anti-viral agents such as didanosine showed superior efficacy over trial groups that did not incorporate it [13] . The explanation for this is that, when a compound suppresses the activity of CD4+ cells, it is likely that activated (antigen presenting) and bystander cells (which are mostly affected by HIV apoptosis [43] are reduced such that these cells are not primed for killing by HIV leading to an overall steady state that is beneficial to the host. Such treatment strategies are encouraged as first-line combinations to reduce the emergence of resistant strains and at a point when the patients are asymptomatic so as to avoid complications that could arise in advance disease [26] .
Fig. 6
We therefore suggest that compound 4 (and possibly 3) has antiviral activity as a result of its cytostatic and suppressive effect on immune activation and that if combined at the right dose with an anti-HIV agent e.g. didanosine, should prove promising in the combination therapy known as virostatics. Such a strategy of fighting HIV represents a novel approach of targeting HIV from multiple directions [20] with the most significant benefit being a better resistant profile.
Lipophilicity studies
Lipophilicity (Log P or AlogP98) is used to assess biological parameters relevant to drug action such as lipid solubility, tissue distribution, receptor binding, cellular uptake, metabolism and bioavailability [44] . As an important physicochemical property in drug design it plays a major role in the ADMET properties of potential drugs. The Log P of complexes 3 and 4 using a modified shake flask method was 0.97±0.5 and 2.42±0.6
while AlogP98 predictions were 0.8 and 1.5 respectively. These values are within the ideal lipophilicity range of 0≥3, unlike log P values of <0 which represents poor lipid bilayer permeability and >3 which represents poor aqueous solubility [45] . The slight differences between lipophilicity values obtained by the shake flask method and those from the in silico prediction studies might be as a result of the presence of the gold atom in the complexes which are not included in the ADMET AlogP98 protocol (resulting from the AlogP98 unknowns - Table S3 ). This is because the program was designed from datasets involving organic molecules [44] . However, this does not seem to have had a drastic effect on the lipophilicity predictions from DS ® Client 2.5 compared to those from the shake flask method. As controls in the in silico assay, the ALogP98 of auranofin and that of the anti-HIV agent nevirapine were also determined and resulted in values of 1.4 and 2.29 respectively (Table S3 ). These findings were in agreement with the literature e.g. auranofin's lipophilicity value was within the ideal range and its use as an orally available RA drug is due to this property [46] while nevirapine's ability to cross the blood brain barrier is also ascribed to its lipophilic nature [47] . These findings therefore validate the in silico predictions for the complexes. Details for other drug-like predictions that were obtained with the in silico ADMET protocol are provided in the supplementary section (Table S3 ).
CONCLUSIONS
Four new bis(thiosemicarbazonate) gold ( Cytostatic agents generally exert activity through inhibition of enzymes other than RT [13] e.g. RNR [19] . These agents are known for lowering CD4+ expression and T cell 
GRAPHICAL ABSTRACT SYNOPSIS
Viral infectivity inhibition at cytostatic concentrations by two of four newly synthesized gold(III) thiosemicarbazonate compounds is due to the effect of the compounds on host cell mechanisms rather than a direct anti-viral ability. These findings suggest the incorporation of these novel compounds in an emerging class of antiviral agents known as virostatics which promise better resistance profiles.
Inhibition of viral infectivity at cytostatic concentrations by two of four gold(III) thiosemicarbazonate compounds is due to compound effects on host cell mechanisms rather than direct anti-viral ability. These findings suggest the incorporation of these novel compounds in the emerging antiviral combination called virostatics which promise better resistance profiles.
1= Viral infectivity inhibition, 2= cytostasis
Complex 4
